ABSTRACT: Signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for cancer therapy. In this study, a series of 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives (CBT) were designed to inhibit the STAT3 SH2 domain phosphorylation site Try 705. We demonstrated that incorporation of basic flexible groups through amide bond linkage to benzo[b]thiophene 1,1-dioxide (BTP) achieved compounds with higher antiproliferative potency than BTP itself. The most potent compound 6o, as indicated from luciferase reporter gene assay, inhibited the STAT3 pathway by decreasing the phosphorylation level of STAT3 Tyr705, while the phosphorylation level of other upstream tyrosine kinases in this pathway was not significantly inhibited. Compound 6o was also shown to trigger ROS generation and accumulation, thus consequently attributed partially to the observed cell apoptosis. This study provided important structural information for the development of inhibitors targeting the STAT3 pathway.
S ignal transducer and activator of transcription 3 (STAT3), one of seven different STAT isoforms (STAT1−6), regulates many critical functions in human normal and malignant tissues, such as cell proliferation, differentiation, apoptosis, immune response, and angiogenesis. 1−5 Upon binding to membrane-bound receptors, the STATs are brought into close proximity for the phosphorylation of the critical tyrosine residue (Tyr 705), the phosphorylated STAT3 undergoes dimerization through a reciprocal pTyr-SH2 domain interaction to form transcriptionally active STAT:STAT dimer, which translocates into the nucleus and binds to specific DNAresponse elements to promote STAT3 target gene transcription. 6 Aberrant activation of STAT3 is reported in many human solid and hematological tumors, including ovarian, breast, colon, pancreatic, lung, brain, renal, and prostate cancers. 7−9 On account of its crucial role in malignant transformation and tumorigenesis, STAT3 has emerged as a promising tumor therapeutic target. 10−15 The first reported small molecule STAT3 inhibitor is STA21 (Figure 1 ), which is discovered to inhibit STAT3-dependent luciferase activity in breast and ovarian cancer cell lines. 16 Derived from STA21, compound LLL12 (Figure 1 ) also shows inhibitory effect on STAT3 phosphorylation, STAT3-DNA binding, and STAT3-dependent transcriptional activity. 17−19 In addition, the substituted 1,4-naphthoquinone-based compound Ly5 and PD15 have been revealed to inhibit STAT3 pTyr705 phosphorylation. 20 Another structurally different skeleton like Stattic (Figure 1 ) is discovered as a STAT3 SH2 domain inhibitor, which selectively suppresses STAT3 protein activation, dimerization, and nuclear translocation in numerous cancer cell lines. 21 Structurally similar to Stattic, compound HJCo146 was also discovered to be a STAT3 inhibitor. 22 Other reported small molecules targeting the STAT3 signaling pathway include: Carbazole, 23 Niclosamide, 24,25 S3I-201,
26,27
NSC-743380, 28, 29 and so on. Most of the reported STAT3 inhibitors are demonstrated to target the pTyr-SH2 domain site Tyr705. Despite these reported efforts, none of these STAT3 inhibitors have been developed into a clinical trial, most possibly due to the lack of ideal physicochemical properties of the studied molecules.
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To develop selective and potent STAT3 inhibitors, the benzo[b]thiophene 1,1-dioxide, as in Stattic, was employed as a leading scaffold. Previous studies have shown that this compound binds to the cleft of the STAT3 SH2 domain (PDB code 1BG1), 21 which primarily consists of three sits: the polar and basic pTyr705 site, the adjacent hydrophobic side pocket, and the Leu706 site. 30, 31 By molecular docking analysis ( Figure S1 ), it was envisioned that attachment of aromatic/ aliphatic moiety at 2-position through different chemical tethers (linker), such as amide, carbonyl, and ester (Figure 1) , would enforce the BTP-protein interaction and consequently improve the compound biological potency and binding selectivity. For these reasons, a series of 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives (CBT) were designed and synthesized, and their antiproliferative activity as well as the inhibitory effect toward the STAT3 pathway were studied. In addition, the biological effect of Stattic was shown to be associated with the formation of reactive oxygen species (ROS). 32, 33 Therefore, the CBT were evaluated on their ability to induce ROS generation. Collectively, this study led to the identification of CBT-based potent inhibitors targeting the STAT3 pathway.
Treatment of the substituted 2-fluorobenzaldehyde (1a−1d) with methyl ethyl 2-mercaptoacetate and potassium carbonate in N,N-dimethylformamide(DMF) at 60°C resulted in the formation of methyl benzo[b]thiophene-2-carboxylate (2a− 2d), and those were conveniently hydrolyzed to provide the corresponding acids 3a−3d (Scheme 1). Using 1-ethyl-3-(3-dimethyllaminopropyl)carbodiiehydrochlide (EDC) as coupling reagent, the acids (3a−3d or benzoic acid) were reacted with either aromatic amines or aliphatic amines to afford intermediates benzo[b]thiophene-2-carboxanilide (4a−4k, 4t, 4u). Compound p-tolyl 4-bromobenzo[b]thiophene-2-carboxylate (4l) was prepared by coupling of 4-bromobenzo[b]-thiophene-2-carboxylic acid (3a) with p-cresol in the presence of DCC and DMAP. Intermediates 4m−4s and 4v were prepared from 3b and 3d with the corresponding secondary amines using EDC and 1-hydroxybenzotriazole (HOBt) as coupling reagents. Treatment of 4g and 4v with Pd/C gave compounds 5a and 5v, which were coupled with benzoic acid to give 4t and 4u. Finally, all benzo[b]thiophenes were oxidized to 2-carbonylbenzo[b]thiophene 1,1-dioxides using m-chloroperbenzoic acid (m-CPBA) as the oxidant.
We first evaluated the antiproliferative activity of these compounds against selected cancer cell lines, which are reported with overexpression of STAT3 protein: breast cancer cell lines include MCF-7 (ER-positive), MDA-MB-231 (ERnegative and triple-negative), and MDA-MB-435S (ER-negative and triple-negative), and nonbreast cancer cell lines include the prostate cancer cell line DU145, the pancreatic cancer cell line PANC-1, and the nonsmall cell lung cancer cell line A549. The established MTT assay was used to determine the compound IC 50 values with Stattic as positive control. As shown in Table  1 , except 6l, all prepared compounds exhibited significant antiproliferative activity against most tested cancer cells, with IC 50 s in single digit micromole range. For compound 6l, the pcresol has an ester linkage with 4-bromobenzo[b]thiophene-2-carboxylic acid and showed the weakest inhibitory activity. All other compounds with the amide linkage ensured their good antiproliferative activity. Apparently, a variety of aliphatic amines at the position of R 4 were well tolerated (6i, 6j, and 6m−6s). These compounds exhibited higher activity against all selected cancer cells. This result was consistent with our molecular docking analysis. By comparison, aromatic amines at R 4 resulted in derivatives with relatively low potency (6a−6g and 6t). In addition, large size substituents at R 2 or R 4 exerted unfavorable influence on the potency of compounds (6g, 6k, 6t, and 6u).
To demonstrate whether or not these compounds would show the expected selectivity between normal cell vs cancer cell, the IC 50 s of compounds 6a, 6j, and 6o against normal human liver cell HL-7702 and liver cancer cell line SMMC- 
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Letter 7721 were determined. As presented in Figure 2A , their IC 50 values were 2.4−6.0 μM against liver cancer cell line SMMC-7721. By comparison, the IC 50 s against normal human liver cell line HL-7702 were 15−25 μM, suggesting that these compounds exhibited high toxicity and good selectivity for cancer cells.
Based on the IC 50 values in Table 1 , compound 6o was selected to investigate the mechanism of inhibition by using STAT3-dependent dual luciferase reporter assay in HeLa cells, which expresses a high level of constitutive STAT3. As shown in Figure 2B , 6o inhibited STAT3 activity in a concentrationdependent manner. Compound 6o at 2 μM decreased 14% of the STAT3-induced luciferase activity; when the concentration of 6o was doubled to 4 μM, the luciferase activity was decreased by 48%, which was higher than the positive STAT3 inhibitor Stattic. At the same concentration, Stattic was decreased by 36%. These results indicated that 6o displayed a remarkable inhibitory effect on STAT3-induced luciferase activity in HeLa cells.
The effect of 6o on the intracellular STAT3 activation was further investigated using Western blot analysis. The MDA-MB-231 breast cancer cells were treated with 6o for 12 h, the total cell lysates were prepared and the Y705 phosphorylated STAT3 proteins were detected using specific antibody. As shown in Figure 2C −E, phosphorylation of Tyr705 was inhibited by 6o in a dose-dependent manner, while the total level of STAT3 protein was not affected at these concentrations. Moreover, 6o displayed higher inhibitory effect on STAT3 phosphorylation than Stattic in all the tested cells ( Figure 2C−E) . By contrast, 6o did not show marked inhibition on the phosphorylation of other kinases including Src, Erk1/2, and mTOR ( Figure 3A) , which are all involved in 
Letter the STAT3 signaling pathway. These results thus indicated that 6o could effectively inhibit the STAT3 phosphorylation in a manner probably independent of these associated kinases ( Figure S2 ).
To further evaluate the inhibition of 6o on STAT3 activity, MDA-MB-231 and MCF-7 cells were starved overnight, followed by treatment with 6o for 2 h before IL-6 stimulation. As shown in Figure 2F , IL-6 markedly increased the phosphorylation level of STAT3, which was decreased by 6o in a concentration-dependent manner. Compound 6o at 4 μM almost completely abolished STAT3 phosphorylation induced by IL-6. These results revealed that 6o effectively inhibited IL-6-induced STAT3 phosphorylation ( Figure S3 ).
To investigate whether 6o could induce apoptosis, the poly(ADP-ribose) polymerase (PARP) was used as a characteristic indication to demonstrate the early apoptotic event in the intact cells. After treatment of MDA-231 cells with 6o, cleavage of PARP protein was determined by Western blot analysis. Notably, 6o elevated the cleaved PARP levels in a time-and concentration-dependent manner ( Figure 3B,C) . In addition, cleavage of PARP was also observed in both MDA-MB-435S and MCF-7 cells with 6o treatment (Figure 3D ).
The percentages of apoptotic cells were further determined by flow cytometry. As shown in Figure 3E , the percentage of the apoptotic cells increased in a concentration-dependent manner after treatment with compound 6o. In the MDA-MB-231 cells, these values were 10.5%, 32.7%, and 63.1% (early and late apoptosis) at the indicated concentration, while only 4.8% was observed in the control cells. Similarly, the induced apoptosis rates in MCF-7 at 0, 2, 4, and 6 μM were 2.6%, 13.9%, 45.0%, and 75.8%, respectively. These results suggested that compound 6o could efficiently induce cancer cell apoptosis, which partially explained the antiproliferative effect of 6o on human cancer cells ( Figure S4 ).
It was reported that benzo[b]thiophenesulphonamide 1,1-dioxide derivatives could induce reactive oxygen species (ROS)-mediated apoptotic process in tumor cells. 32 To investigate whether or not our newly synthesized derivatives could also induce ROS production, MDA-MB-231 and MCF-7 cells were pretreated with 6o, and then cells were collected and stained by DCFH-DA and subjected to flow cytometry analysis. As shown in Figure 4A , 6o triggered a dose-dependent ROS generation in both MDA-MB-231 and MCF-7 cancer cells, which would partially contribute to the observed PARP protein cleavage and cell apoptosis.
Next, Western blot analysis was conducted to detect whether the 6o-induced cleavage of PARP could be abrogated by addition of a ROS scavenger. The MDA-MB-231 cancer cells were pretreated with an antioxidant, N-acetylcysteine (NAC). Then, compound 6o was added, and PARP was collected and determined. As depicted by Figure 4B , the antioxidant NAC could significantly decrease 6o-induced cleavage of PARP. Besides, 6o could decrease the intracellular GSH content in the MDA-MB-231, which confirmed 6o induced apoptosis partially by interacting with GSH ( Figure S5 ). These results verified our hypothesis that compound 6o could induce the generation and accumulation of ROS, which was possibly involved in the cell apoptosis by interacting with GSH.
In summary, a series of 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives (CBT) were developed to inhibit the phosphorylation of the STAT3. Through incorporation of basic flexible groups to the benzo[b]thiophene 1,1-dioxide (BTP) core structure, higher potency compounds were discovered. We confirmed that the compounds inhibited the phosphorylation of STAT3 and cell proliferation and induced the apoptotic process of cancer cells with constitutively active STAT3. The present study provided more structural reference for the development of a useful tool in elucidating the inhibition of STAT signaling pathway. Further in vivo antitumor activity studies on these compounds are undergoing and will be reported in due course.
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